Bridgefront Capital’s Integra LifeSciences IART Stock Holding History

Bridgefront Capital’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$158K	Buy	+16,779	New	+$184K	0.04%	484
2024 Q4	–	Sell	-11,645	Closed	-$212K	–	677
2024 Q3	$212K	Buy	+11,645	New	+$270K	0.08%	441
2023 Q3	–	Sell	-16,348	Closed	-$672K	–	490
2023 Q2	$672K	Buy	16,348 +12,254	+299%	+$590K	0.36%	66
2023 Q1	$235K	Buy	+4,094	New	+$231K	0.14%	286
2022 Q2	–	Sell	-4,116	Closed	-$264K	–	365
2022 Q1	$264K	Sell	4,116 -2,491	-38%	-$164K	0.32%	138
2021 Q4	$443K	Buy	+6,607	New	+$447K	0.43%	64
2021 Q3	–	Sell	-6,684	Closed	-$456K	–	501
2021 Q2	$456K	Buy	+6,684	New	+$473K	0.17%	208

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bridgefront Capital's IART Position: Q1 2026 in Review

Bridgefront Capital opened a new position in Integra LifeSciences (IART) in Q1 2026: 16,779 shares worth $158K. The stake represents 0.04% of the portfolio and ranks #484 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in IART as recently as Q3 2024.

Bridgefront Capital first reported a position in IART in Q2 2021 and has held it in 7 quarters since. The position peaked at $672K in Q2 2023. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

Bridgefront Capital held 16,779 shares of Integra LifeSciences worth $158K as of Q1 2026.
Integra LifeSciences was a new Bridgefront Capital position in Q1 2026.
Integra LifeSciences made up 0.04% of Bridgefront Capital's portfolio in Q1 2026, its #484 holding.
Bridgefront Capital first reported a position in Integra LifeSciences in Q2 2021 and has held it in 7 quarters since.
Bridgefront Capital's Integra LifeSciences position peaked at $672K in Q2 2023.
201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.